ORLANDO – Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, a researcher ...
June 13, 2006 -- The U.S. Food and Drug Administration (FDA) has approved a 2000-IU (5-mL) dose for antihemophilic factor VIII [recombinant] infusion; and an expanded indication for infliximab ...
The US Food and Drug Administration (FDA) has approved infliximab-dyyb (Zymfentra, Celltrion USA) for maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) and Crohn ...
SEATTLE — Patients with proliferative vitreoretinopathy experienced improved visual acuity after receiving an intravitreal injection of infliximab after pars plana vitrectomy, according to a study. At ...
Original Medicare covers most medically necessary treatments for rheumatoid arthritis (RA), including biologics like adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Inflectra), and ...
What Is Infusion for Ulcerative Colitis? If your doctor has recommended infusion therapy, this is probably because standard treatment hasn’t helped relieve symptoms caused by moderate-to-severe ...
INCHEON, South Korea--(BUSINESS WIRE)--Celltrion today announced two-year results of subcutaneous infliximab (CT-P13 SC) dose escalation therapy at United European Gastroenterology (UEG) Week 2024 in ...
Sept 20 (Reuters) - Pfizer Inc on Wednesday filed a lawsuit against Johnson & Johnson, saying that the drugmaker's anticompetitive contracts with health insurers prevented biosimilar competition to ...
NEW YORK, Sept 7 (Reuters) - Merck & Co said an arbitration panel would look in late September at whether the company is entitled to overseas rights to Remicade and Simponi, Johnson & Johnson's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback